Showing 5751-5760 of 6632 results for "".
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- Alana Sine is New CFO at Merz North Americahttps://practicaldermatology.com/news/alan-sine-is-new-cfo-at-merz-north-america/2457719/Merz North America has appointed Alana Sine as Chief Financial Officer (CFO), Merz North America. Ms. Sine has served as interim CFO since March 2018. Ms. Sine will lead the finance function for North America, overseeing finan
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- Xact Nabs Best of Hot Topics at ASAPS 2018https://practicaldermatology.com/news/xact-nabs-best-of-hot-topics-at-asaps-2018/2457727/Cypris Medical, Inc.’s Xact technology took home the “Best of Hot Topics” award at the American Society for Aesthetic Plastic Surgery (ASAPS) meeting in New York. Xact technology is a minimally invasive face and neck lifting suturing d
- PellePharm Presents New Data in BCChttps://practicaldermatology.com/news/pellepharm-presents-new-data-in-bcc/2457731/PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs at the International Investigative Dermatology (IID) Meeting in Orlando, FL. The data, presented i
- InMode: New EmbraceRF Solution Introduces Subdermal Adipose Remodelinghttps://practicaldermatology.com/news/inmode-new-embracerf-solution-introduces-subnormal-adipose-remodeling/2457733/Introducing the concept of Subdermal Adipose Remodeling, InMode Aesthetic Solutions is launching EmbraceRF to target the neck and face through a powerful combination of
- White Coats, Scrubs Top Patient Preferences for Doctor's Attirehttps://practicaldermatology.com/news/white-coats-scrubs-top-patient-preferences-for-doctors-attire/2457735/What doctors wear matters…a lot, according to the largest-ever study of patient preferences for doctors’ attire. Just more than half of the 4,062 patients surveyed in the clinics and hospitals of ten major medical centers said that what physicians wear is important to th
- Gryphon Investors Makes Majority Investment in Water's Edge Dermatologyhttps://practicaldermatology.com/news/gryphon-investors-makes-majority-investment-in-waters-edge-dermatology/2457741/Gryphon Investors has made a majority investment in Water’s Edge Dermatology. Terms of the transaction were not disclosed. Gryphon Investors is a San Francisco-based middle market private equity firm. A leading provider of comprehensive dermatology services in over 30
- PD1 Blocker Shrinks Advanced Squamous Cell Skin Cancershttps://practicaldermatology.com/news/pd1-blocker-shrinks-advanced-squamous-cell-skin-cancers/2457737/A checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of squamous cell carcinoma, an international team reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of pa